Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 1/20 | 1.00 |
| ▸ | PRKACA | P17612 | 1/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 1.00 |
| ▸ | LTK | P29376 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15333160 | 0.83 | METAP2 (1.00) | CHEK1PIM1FLT3JAK2AURKA | |
| SCHEMBL31456431 | 0.83 | METAP2 (1.00) | CHEK1PIM1FLT3JAK2AURKA | |
| SCHEMBL2457623 | 0.82 | CHEK1 (0.69) | CHEK1PIM1FLT3JAK2AURKA | |
| SCHEMBL182445 | 0.75 | JAK2 (0.60) | CHEK1PIM1FLT3JAK2AURKA | |
| SCHEMBL612899 | 0.74 | DAO (0.70) | CHEK1PIM1FLT3JAK2AURKA | |
| SCHEMBL12241447 | 0.74 | CHEK1 (0.59) | CHEK1PIM1FLT3JAK2AURKA | |
| SCHEMBL3924921 | 0.74 | CHEK1 (0.59) | CHEK1PIM1FLT3JAK2AURKA | |
| SCHEMBL4950054 | 0.74 | DAO (0.70) | CHEK1PIM1FLT3JAK2AURKA | |
| SCHEMBL3906637 | 0.74 | RPS6KA3 (0.59) | CHEK1PIM1FLT3JAK2AURKA | |
| SCHEMBL1396317 | 0.72 | CHEK1 (0.56) | CHEK1PIM1FLT3JAK2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235733-A1 | BIS-BICYCLOHETEROARYL MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4558492-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4330257-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2025-03-19 | — | — | EP | disclosed |
| CN-119654315-A | 3- (6-Pyridin-3-yl) -2- [4- (4-methyl-4H-1, 2, 4-triazol-3-yl) piperidin-1-yl ] benzonitrile derivatives and similar compounds as QPCTL and QPCT inhibitors for the treatment of cancer | 858治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240246983-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2024-07-25 | — | — | US | disclosed |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | 858 THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2022229234-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2022-11-03 | — | — | WO | disclosed |
| EP-3126350-B1 | ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2018-07-04 | — | — | EP | disclosed |
| US-9908868-B2 | Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2018-03-06 | — | — | US | disclosed |
| WO-2017046318-A1 | TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081323-A1 | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-03-23 | — | — | US | disclosed |
| US-20170022182-A1 | ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2017-01-26 | — | — | US | disclosed |
| CN-106164068-A | Isoindolinone compounds as the GPR119 regulator for the treatment of diabetes, obesity, dyslipidemia and associated conditions | 赛诺菲 | 2016-11-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022182-A1 | ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | GPR119, GPR65, GPR88 | CHEK1 4710/4885PIM1 3889/4885FLT3 3880/4885 |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | ACAT1, ACAT2, LCAT | CHEK1 2073/4885PIM1 3232/4885FLT3 2859/4885 |
| US-20170081323-A1 | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | OAT, XDH, MAPT | CHEK1 1722/4885PIM1 4523/4885FLT3 1244/4885 |
| US-20240246983-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | NES, NUDC, NCL | CHEK1 3459/4885PIM1 1675/4885FLT3 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.